Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
This article was originally published in The Tan Sheet
Executive Summary
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
You may also be interested in...
ADAPT Data Linking Naproxen To Heart Risk Is “Not Reliable” – Nissen
The premature halting of the ADAPT trial and subsequent safety concerns for naproxen were "inappropriate and reflected faulty logic," according to Cleveland Clinic cardiologist Steven Nissen, MD
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
ADAPT Naproxen Signal “Not Sufficiently Compelling” To Halt Trial – Speaker
The halting of the NIH-sponsored ADAPT trial, which suggested that naproxen may be linked to an elevated cardiovascular risk, was due more to external factors and safety concerns surrounding the COX-2 class than the study data themselves